Trial Profile
Efficacy of Erlotinib, Gefitnib and Afatinib in patient with advanced non-small cell lung cancer (NSCLC) with common mutations and uncommon mutations.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2017
Price :
$35
*